Gosset CRM197 carrier protein Overview
CRM197 is a **non-toxic mutant form of diphtheria toxin** produced by a single amino acid substitution (G52E), which abolishes its ADP-ribosylation activity and thus eliminates toxicity while preserving structural similarity to native diphtheria toxin[1][2][3]. It serves as an **immunogenic carrier protein** in many licensed conjugate vaccines, where it is covalently linked to weakly immunogenic polysaccharides or haptens from pathogenic bacteria. This linkage enables robust **helper T cell activation**, leading to enhanced antibody production against the target pathogen. CRM197 does not function as a classical therapeutic target such as an enzyme or receptor but rather acts indirectly by facilitating antigen processing and presentation within the context of vaccination. Its widespread use includes pediatric vaccines targeting *Haemophilus influenzae* type b, *Streptococcus pneumoniae*, and *Neisseria meningitidis*[1][2]. A notable challenge with repeated exposure is the potential development of strong anti-carrier immunity, which could impact future vaccine efficacy if multiple products use CRM197 as their carrier[2]. **Note:** The phrase "Helper T cell activation via CRM197 carrier protein" describes an immunological process rather than a discrete molecular target. The actual molecule here—CRM197—is not itself a receptor or signaling molecule but functions structurally within vaccine formulations. Therefore, this entry should be flagged as incorrect for standard therapeutic target databases.
Mechanism of Action
Biological Functions
Disease Associations
Safety Considerations
- Potential for anti-carrier immune responses that may reduce effectiveness of subsequent vaccines using the same carrier
- Not used therapeutically on its own; safety concerns relate primarily to its use in repeated vaccinations